Study title:
A 7 -Day, Open-Label, Multicenter, Pharmacokinetic study (Part 1) followed by a 7-Day, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study (Part 2) of IV Sildenafil in the treatment of neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure and at risk for PPHN.
Type of medicine: Centrally authorised medicines
|
Therapeutic area: Cardiovascular Diseases
|
Brands: Please see report, Please see report, Please see report |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: sildenafil |
ATC code: G04BE03 |
Document link:
A1481157 PhRMA Web Synopsis.pdf
|
Document date: 2013-10-01
|
Study number: A1481157 |
EudraCT number:
|
Scope of study: CLINICAL |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
Y
|
-
|
-
|
-
|